Biotech Growth Slows As Cost Containment Hits Home
EY Lifesciences annual report into the biotech industry released in time for BIO finds a shift in capital flows as funds from China and the UK began to make their mark. Cost containment hit revenue growth and net income declined, while industry was told to embrace new technologies to thrive long term.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.